Stock Research for SRPT

SRPT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SRPT Stock Chart & Research Data

The SRPT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SRPT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SRPT Due diligence Resources & Stock Charts

The SRPT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SRPT Detailed Price Forecast - CNN Money CNN View SRPT Detailed Summary - Google Finance
Yahoo View SRPT Detailed Summary - Yahoo! Finance Zacks View SRPT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View SRPT Trends & Analysis - Trade-Ideas Barrons View SRPT Major Holders - Barrons
NASDAQ View SRPT Call Transcripts - NASDAQ Seeking View SRPT Breaking News & Analysis - Seeking Alpha
Spotlight View SRPT Annual Report - CompanySpotlight.com OTC Report View SRPT OTC Short Report - OTCShortReport.com
TradeKing View SRPT Fundamentals - TradeKing Charts View SRPT SEC Filings - Bar Chart
WSJ View Historical Prices for SRPT - The WSJ Morningstar View Performance/Total Return for SRPT - Morningstar
MarketWatch View the Analyst Estimates for SRPT - MarketWatch CNBC View the Earnings History for SRPT - CNBC
StockMarketWatch View the SRPT Earnings - StockMarketWatch MacroAxis View SRPT Buy or Sell Recommendations - MacroAxis
Bullish View the SRPT Bullish Patterns - American Bulls Short Pains View SRPT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View SRPT Stock Mentions - StockTwits PennyStocks View SRPT Stock Mentions - PennyStockTweets
Twitter View SRPT Stock Mentions - Twitter Invest Hub View SRPT Investment Forum News - Investor Hub
Yahoo View SRPT Stock Mentions - Yahoo! Message Board Seeking Alpha View SRPT Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for SRPT - SECform4.com Insider Cow View Insider Transactions for SRPT - Insider Cow
CNBC View SRPT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SRPT - OTC Markets
Yahoo View Insider Transactions for SRPT - Yahoo! Finance NASDAQ View Institutional Holdings for SRPT - NASDAQ


Stock Charts

FinViz View SRPT Stock Insight & Charts - FinViz.com StockCharts View SRPT Investment Charts - StockCharts.com
BarChart View SRPT Stock Overview & Charts - BarChart Trading View View SRPT User Generated Charts - Trading View


Latest Financial News for SRPT

Why Big Biotech Stocks May Get An Earnings Boost
Posted on Wednesday April 18, 2018

Big Bounce: Big biotech stocks may surge on better-than-expected quarterly results


How BTCY Could Look a Lot Like SRPT in a Year's Time
Posted on Wednesday April 18, 2018

- Sarepta Therapeutics (SRTP) faced headwinds as they brought their new drug Exondys 51 to the market in the last two years, but the company and its stock have done very well with great execution on the sales front, and in expanding their drug candidate portfolio. - Investors like to see this kind of diversification as revenue begins to pile up, and the stock has gone from $25 to $80 in less than two years. - Unknown Biotricity (BTCY) is in a similar position, launching their first FDA cleared product and expanding their planned product offerings this year with new medical devices in development.


See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
Posted on Monday April 16, 2018

Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. The net inflows of $171 million over the last one-month into ETFs that hold SRPT are among the lowest of the last year and appear to be slowing.


Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
Posted on Thursday April 12, 2018

All three companies are developing drugs made up of a shortened version of the dystrophin gene, which normally protects muscle cells but is absent in boys with Duchenne.


Enter a stock symbol to view the stock details.